China Pharma Holdings (CPHI) Free Cash Flow (2010 - 2026)
China Pharma Holdings (CPHI) posted Free Cash Flow of -$55292.0 for Q1 2026, down 136.49% on a QoQ basis from $151536.0 in Q4 2025, and up 58.11% year-over-year from -$34970.1 in Q1 2025.
China Pharma Holdings (CPHI) Free Cash Flow (2010 - 2026) Analysis & Trends
China Pharma Holdings' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$55292.0 for Q1 2026.
- Quarterly Free Cash Flow rose 58.11% year-over-year to -$55292.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165645.0 (up 350.49% YoY) and the FY2025 annual result came in at $88937.0, up 120.01% from the prior year.
- Free Cash Flow was -$55292.0 for Q1 2026 at China Pharma Holdings, down from $151536.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $939831.0 in Q3 2023 and bottomed at -$1.4 million in Q1 2023.
- A 5-year average of -$112085.6 and a median of -$55292.0 in 2026 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 2911.59% — and 2025, when it plunged 529.7%.
- China Pharma Holdings' Free Cash Flow stood at $611862.0 in 2022, then plunged by 104.39% to -$26850.0 in 2023, then soared by 1139.96% to $279228.0 in 2024, then tumbled by 45.73% to $151536.0 in 2025, then sank by 136.49% to -$55292.0 in 2026.
- Business Quant data shows CPHI's Free Cash Flow at -$55292.0 in Q1 2026, $151536.0 in Q4 2025, and -$237598.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -55,292.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55,292.00 |
| Mar 31, 2026 | -55,292.00 |
| Dec 31, 2025 | 151,536.00 |
| Dec 31, 2025 | 151,536.00 |
| Sep 30, 2025 | -237,598.00 |
| Sep 30, 2025 | -237,598.00 |
| Jun 30, 2025 | 306,999.00 |
| Jun 30, 2025 | 306,999.00 |
| Mar 31, 2025 | -132,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Dec 31, 2024 | 279,228.00 |
| Dec 31, 2024 | 279,228.00 |
| Sep 30, 2024 | -37,732.00 |
| Sep 30, 2024 | -37,732.00 |
| Jun 30, 2024 | -72,726.00 |
| Jun 30, 2024 | -72,726.00 |
| Mar 31, 2024 | -585,158.00 |
| Mar 31, 2024 | -585,158.00 |
| Dec 31, 2023 | -26,850.00 |
| Dec 31, 2023 | -26,850.00 |